SCLEROSI MULTIPLA: VICINI AD UNA SVOLTALiberoQuotidiano.itDAC HYP (daclizumab high yeld process): è una terapia sottocutanea mensile, attualmente al centro di studi di fase 3, per il trattamento della SMRR (sclerosi multipla recidivante-remittente). E…
Through 2021, The Number of Disease-Modifying Therapies Approved for The … – MarketWatch (press release)
Through 2021, The Number of Disease-Modifying Therapies Approved for The …MarketWatch (press release)However, Decision Resources expects outstanding safety concerns will constrain the adoption of these potentially high-risk/high-reward therapies by a…
Face transplant recipient impresses doctors seven months after surgery
"I can now go out and not get the stares and have to hear comments that people would make," said Richard Lee Norris
Genetic clues for responders to heart failure drug identified – News-Medical.net
Genetic clues for responders to heart failure drug identifiedNews-Medical.netBy Piriya Mahendra, medwireNews Reporter. Researchers have identified genetic signatures that predict which patients respond to the beta blocker bucindolol. Stephen Liggett (U…
Majid Al Futtaim Ventures partners with the Dubai Health Authority to donate … – Al-Bawaba
Majid Al Futtaim Ventures partners with the Dubai Health Authority to donate …Al-BawabaMore than 100 passionate individuals volunteered to give blood in a company-wide blood donation drive organised by Majid Al Futtaim Ventures, the growth engine res…
How overeating leads to diabetes and obesity – Times of India
How overeating leads to diabetes and obesityTimes of IndiaIncreased fatty acids induce inflammation and that, in turn, can further worsen insulin resistance, which is the core defect in type 2 diabetes. Fatty acids also increase glucose production in t…
AstraZeneca launches heart drug `Brilinta` in India – Zee News
Zee NewsAstraZeneca launches heart drug `Brilinta` in IndiaZee NewsAstraZeneca launches heart drug `Brilinta` in India. New Delhi: AstraZeneca Pharma India on Thursday launched its patented antiplatelet drug Brilinta, used to prevent heart attack, afte…
Samsung halts biosimilar rituximab trial on regulatory concerns – In-PharmaTechnologist.com
In-PharmaTechnologist.comSamsung halts biosimilar rituximab trial on regulatory concernsIn-PharmaTechnologist.comThe JV formed through the deal is focused on developing biosimilar versions of marketed products which – evidently – included a version of …
Documentary stirs debate on organ donation – The Copenhagen Post
The Copenhagen PostDocumentary stirs debate on organ donationThe Copenhagen PostThe hospital stated that there is no risk of a false diagnosis of brain death and stressed that people should not worry that their organs will be harvested unless they are …
AstraZeneca launches heart drug 'Brilinta' in India – Economic Times
Moneycontrol.comAstraZeneca launches heart drug 'Brilinta' in IndiaEconomic TimesNEW DELHI: AstraZeneca Pharma India today launched its patented antiplatelet drug Brilinta, used to prevent heart attack, after receiving approval from the Drug Co…